Results 11 to 20 of about 56,467 (180)

Natalizumab for relapsing remitting multiple sclerosis [PDF]

Cochrane Database of Systematic Reviews, 2009
Natalizumab (NTZ) (Tysabri(®)) is a monoclonal antibody that inhibits leukocyte migration across the blood-brain barrier, thus reducing inflammation in central nervous system, and has been approved worldwide for the treatment of relapsing-remitting multiple sclerosis (RRMS).To evaluate the efficacy, tolerability and safety of NTZ in the treatment of ...
Pucci, Eugenio, Giuliani, Giorgio, Solari, Alessandra, Simi, Silvana, Minozzi, Silvia, Di Pietrantonj, Carlo, Galea, Ian   +6 more
openaire   +4 more sources

Delayed P100-Like Latencies in Multiple Sclerosis: A Preliminary Investigation Using Visual Evoked Spread Spectrum Analysis. [PDF]

PLoS ONE, 2016
Conduction along the optic nerve is often slowed in multiple sclerosis (MS). This is typically assessed by measuring the latency of the P100 component of the Visual Evoked Potential (VEP) using electroencephalography.
Hanni S M Kiiski, Sinéad Ní Riada, Edmund C Lalor, Nuno R Gonçalves, Hugh Nolan, Robert Whelan, Róisín Lonergan, Siobhán Kelly, Marie Claire O'Brien, Katie Kinsella, Jessica Bramham, Teresa Burke, Seán Ó Donnchadha, Michael Hutchinson, Niall Tubridy, Richard B Reilly   +15 more
doaj   +1 more source

Modern Technology in Multi-Shell Diffusion MRI Reveals Diffuse White Matter Changes in Young Adults With Relapsing-Remitting Multiple Sclerosis

Frontiers in Neuroscience, 2021
ObjectiveTo characterize microstructural white matter changes related to relapsing-remitting multiple sclerosis using advanced diffusion MRI modeling and tractography.
Ann-Marie Beaudoin, François Rheault, Guillaume Theaud, Frédéric Laberge, Kevin Whittingstall, Albert Lamontagne, Maxime Descoteaux   +6 more
doaj   +1 more source

Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis [PDF]

JAMA Neurology, 2023
ImportanceOcrelizumab, a humanized monoclonal antibody targeted against CD20+ B cells, reduces the frequency of relapses by 46% and disability worsening by 40% compared with interferon beta 1a in relapsing-remitting multiple sclerosis (MS). Rituximab, a chimeric monoclonal anti-CD20 agent, is often prescribed as an off-label alternative to ocrelizumab ...
Roos, Izanne, Hughes, Stella, McDonnell, Gavin, Malpas, Charles B., Sharmin, Sifat, Boz, Cavit, Alroughani, Raed, Ozakbas, Serkan, Buzzard, Katherine, Skibina, Olga, van der Walt, Anneke, Butzkueven, Helmut, Lechner-Scott, Jeannette, Kuhle, Jens, Terzi, Murat, Laureys, Guy, Van Hijfte, Liesbeth, John, Nevin, Grammond, Pierre, Grand'Maison, Francois, Soysal, Aysun, Jensen, Ana Voldsgaard, Rasmussen, Peter Vestergaard, Svendsen, Kristina Bacher, Barzinji, Ismael, Nielsen, Helle Hvilsted, Sejbæk, Tobias, Prakash, Sivagini, Stilund, Morten Leif Munding, Weglewski, Arkadiusz, Issa, Nadia Mubder, Kant, Matthias, Sellebjerg, Finn, Gray, Orla, Magyari, Melinda, Kalincik, Tomas, null, null, Cabrera-Gomez, Jose Antonio, Roullet, Etienne, Zwanikken, Cees, Den braber-Moerland, Leontien, Barnett, Michael, Hodgkinson, Suzanne, Garber, Justin, Slee, Mark, McCombe, Pamela, Taylor, Bruce, MacDonell, Richard, Massey, Jennifer, Van Pesch, Vincent, Decoo, Danny, Willekens, Barbara, Fragoso, Yara, Prevost, Julie, Prat, Alexandre, Girard, Marc, Grammond, Pierre, Larochelle, Catherine, Oh, Jiwon, Lalive, Patrice, Gobbi, Claudio, Horakova, Dana, Havrdova, Eva, Ampapa, Radek, Izquierdo, Guillermo, Eichau, Sara, Sanchez-Menoyo, Jose L., Ramo-Tello, Cristina, Blanco, Yolanda, Saiz, Albert, Besora, Sarah, Shaygannejad, Vahid, Cartechini, Elisabetta, Diamanti, Matteo, Amato, Maria Pia, Spitaleri, Daniele, Patti, Francesco, Chisari, Clara, D'Amico, Emanuele, Salvatore, Lo Fermo, Yamout, Bassem, Khoury, Samia J., Al-Asmi, Abdullah, Jose Sa, Maria, Al-Harbi, Talal, Karabudak, Rana, Turkoglu, Recai, Kilpatrick, Trevor, King, John, Nguyen, Ai-Lan, Dwyer, Chris, Monif, Mastura, Taylor, Lisa, Baker, Josephine   +93 more
openaire   +6 more sources

Primary progressive multiple sclerosis in the Polish population

Aktualności Neurologiczne, 2017
Objectives: The aim of the study was the epidemiological analysis and evaluation of selected clinical and sociodemographic factors in Polish patients with primary progressive multiple sclerosis.
Waldemar Brola, Piotr Sobolewski, Stanisław Flaga, Małgorzata Fudala, Andrzej Potemkowski   +4 more
doaj   +1 more source

Multiple Sclerosis Relapsing Remitting Progressive Type

Jurnal Profesi Medika, 2020
Multiple sclerosis (MS) is the most common neurologic demyelinating disease in high-income countries. The causes of MS is multifactorial involve genetics and the environment in which immune cell infiltration occurs across the blood-brain barrier, causing
Nora Fitri, Basjiruddin Ahmad, Yuliarni Syafrita   +2 more
doaj   +1 more source

EХPERIENCE IN INTERFERON β-1A USE FOR TREATMENT OF MULTIPLE SCLEROSIS IN CHILDREN

Вопросы современной педиатрии, 2013
Aim: to evaluate the impact of subcutaneous interferon β-1a on matrix metalloproteinases 3, 8, 9 (MMP), cytokines (tumor necrosis factor α — TNF α, and transforming growth factor β1 — TGF β1) levels in serum of children with relapsing-remitting multiple ...
L. M. Kuzenkova, L. A. Pak, V.M. Studenikin, N. N. Shatilova, B. I. Bursagova, I. E. Smirnova   +5 more
doaj   +1 more source

Progressive multiple sclerosis: Prospects for disease therapy, repair, and restoration of function [PDF]

, 2017
Multiple sclerosis is a major cause of neurological disability, which accrues predominantly during progressive forms of the disease. Although development of multifocal inflammatory lesions is the underlying pathological process in relapsing-remitting ...
Cohen, JA, Fox, RJ, Ontaneda, D, Thompson, AJ   +3 more
core   +1 more source

Erythropoietin therapy in a case of neonatal anemia after exposure to natalizumab throughout pregnancy

Italian Journal of Pediatrics, 2021
Background Natalizumab is a monoclonal antibody approved for the treatment of patients with relapsing-remitting multiple sclerosis. According to the current clinical recommendations, its use during pregnancy should be carefully evaluated only in women ...
Elisabetta Godano, Fabio Barra, Alessandra Allodi, Antonella Ferraiolo, Alice Laroni, Giovanni Novi, Giovanni Luigi Mancardi, Claudio Gustavino, Cesare Arioni   +8 more
doaj   +1 more source

Intestinal Permeability in Relapsing-Remitting Multiple Sclerosis [PDF]

Neurotherapeutics, 2018
Changes of intestinal permeability (IP) have been extensively investigated in inflammatory bowel diseases (IBD) and celiac disease (CD), underpinned by a known unbalance between microbiota, IP and immune responses in the gut. Recently the influence of IP on brain function has greatly been appreciated. Previous works showed an increased IP that preceded
Buscarinu, M. C., Romano, S., Mechelli, R., Pizzolato Umeton, R., Ferraldeschi, M., Fornasiero, A., ReniÃ, R., Cerasoli, B., MORENA, EMANUELE, Romano, Carmela, Loizzo, N. D., Umeton, R., Salvetti, M., Ristori, G.   +13 more
openaire   +3 more sources